US-based generic drugmaker Mylan Inc is acquiring the women’s health business of Mumbai-based Famy Care for roughly $800 million (around Rs. 4,950 crore)..The acquisition is being made through its Indian unit, Mylan Laboratories Ltd, for $750 million in cash and an additional $50 million in contingent payments, reports Mint..Luthra & Luthra along with Cravath, Swaine & Moore LLP acted for Mylan while AZB & Partners, Crawford Bayley & Company, and Covington & Burling LLP acted for Famy Care..The Luthra team included Partners Mohit Saraf and Sudipta Routh while the Cravath team was led by Partners Mark I. Greene and Minh Van Ngo..The AZB team was led by Partner Shuva Mandal along with Senior Associate Sayak Maity..The Crawford team was led by Senior Partner Sanjay Asher, Principal Associate Bhumika Batra along with Associates Sanskriti Relekar, Anuja Takle, Aparajita Chakraborty and Avanti Kale..The Covington team included Partners Jack Bodner and Ralph C. Voltmer..Hong Kong-based AIF Capital, which has 18 per cent stake in Famy Care, which it bought for Rs 175 crore in 2010 will exit. Platinum Partners and Debevoise & Plimpton LLP advised AIF Capital Limited in the sale of its stake in Famy Care to Mylan. The Platinum team was led by Partner Ankit Majmudar and Debevoise team was led by London-based Partner Geoffrey P. Burgess along Hong Kong-based Associate Parveet Singh Gandoak and London-based Associate Shashwat Patel. .Under the proposed transaction structure, Famy Care will spin off its female healthcare businesses under a court-approved scheme of demerger. After the demerger, Mylan will acquire the shares of the resulting company..The acquisition is expected to give Mylan a significant presence in the women’s healthcare market, particularly in contraceptive products, reports ET..This is Mylan’s second deal with an Indian drugmaker after it bought Bangalore-based Strides Arcolab Ltd’s injectable drugs unit for $1.6 billion in 2013. In that deal, DSK Legal and Herbert Smith Freehills acted for Strides while Mylan was represented by Skadden, Arps, Slate, Meagher & Flom LLP, Slaughter and May, and Platinum Partners..Image taken from here.
US-based generic drugmaker Mylan Inc is acquiring the women’s health business of Mumbai-based Famy Care for roughly $800 million (around Rs. 4,950 crore)..The acquisition is being made through its Indian unit, Mylan Laboratories Ltd, for $750 million in cash and an additional $50 million in contingent payments, reports Mint..Luthra & Luthra along with Cravath, Swaine & Moore LLP acted for Mylan while AZB & Partners, Crawford Bayley & Company, and Covington & Burling LLP acted for Famy Care..The Luthra team included Partners Mohit Saraf and Sudipta Routh while the Cravath team was led by Partners Mark I. Greene and Minh Van Ngo..The AZB team was led by Partner Shuva Mandal along with Senior Associate Sayak Maity..The Crawford team was led by Senior Partner Sanjay Asher, Principal Associate Bhumika Batra along with Associates Sanskriti Relekar, Anuja Takle, Aparajita Chakraborty and Avanti Kale..The Covington team included Partners Jack Bodner and Ralph C. Voltmer..Hong Kong-based AIF Capital, which has 18 per cent stake in Famy Care, which it bought for Rs 175 crore in 2010 will exit. Platinum Partners and Debevoise & Plimpton LLP advised AIF Capital Limited in the sale of its stake in Famy Care to Mylan. The Platinum team was led by Partner Ankit Majmudar and Debevoise team was led by London-based Partner Geoffrey P. Burgess along Hong Kong-based Associate Parveet Singh Gandoak and London-based Associate Shashwat Patel. .Under the proposed transaction structure, Famy Care will spin off its female healthcare businesses under a court-approved scheme of demerger. After the demerger, Mylan will acquire the shares of the resulting company..The acquisition is expected to give Mylan a significant presence in the women’s healthcare market, particularly in contraceptive products, reports ET..This is Mylan’s second deal with an Indian drugmaker after it bought Bangalore-based Strides Arcolab Ltd’s injectable drugs unit for $1.6 billion in 2013. In that deal, DSK Legal and Herbert Smith Freehills acted for Strides while Mylan was represented by Skadden, Arps, Slate, Meagher & Flom LLP, Slaughter and May, and Platinum Partners..Image taken from here.
